Monopar Therapeutics Inc. (MNPR) Current Ratio
- Current ratio · latest quarter: Value 33.56×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 33.56× | Current assets / current liabilities. $134.76M ÷ $4.02M ≈ 33.56× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 134.76M USD | Assets, Current |
| Current obligations | 4.02M USD | Liabilities, Current |
| Cash and equivalents | 52.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 52.61M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $134.76M | $4.02M | $52.76M | $52.61M | (m) | (m) | (m) | (m) | 33.56× |
| 2026-03-31 | $137.74M | $2.46M | $52.54M | $52.37M | (m) | (m) | (m) | (m) | 56.04× |
| 2025-12-31 | $140.46M | $2.74M | $61.83M | $60.88M | (m) | (m) | (m) | (m) | 51.35× |
| 2025-09-30 | $144.09M | $2.57M | $127.68M | $127.50M | (m) | (m) | (m) | (m) | 56.10× |
| 2025-06-30 | $53.75M | $1.58M | $39.50M | $39.33M | (m) | (m) | (m) | (m) | 33.94× |
| 2024-12-31 | $60.29M | $5.25M | $45.82M | $45.53M | (m) | (m) | (m) | (m) | 11.47× |
| 2023-09-30 | $8.57M | $1.98M | $5.52M | $7.65M | (m) | (m) | (m) | (m) | 4.32× |
| 2023-06-30 | $10.30M | $2.50M | $7.21M | $9.11M | (m) | (m) | (m) | (m) | 4.12× |
| 2023-03-31 | $11.78M | $2.89M | $5.73M | (m) | (m) | (m) | (m) | (m) | 4.08× |
| 2022-12-31 | $13.17M | $3.13M | $8.19M | $12.18M | (m) | (m) | (m) | (m) | 4.21× |
| 2022-09-30 | $14.37M | $1.91M | $14.32M | (m) | (m) | (m) | (m) | (m) | 7.51× |
| 2022-06-30 | $16.65M | $2.19M | $16.46M | (m) | (m) | (m) | (m) | (m) | 7.61× |
| 2022-03-31 | $18.01M | $1.07M | $17.82M | (m) | (m) | (m) | (m) | (m) | 16.77× |
| 2021-12-31 | $20.52M | $1.58M | $20.30M | (m) | (m) | (m) | (m) | (m) | 12.98× |
| 2021-03-31 | $25.84M | $806.27K | $25.72M | (m) | (m) | (m) | (m) | (m) | 32.05× |
| 2020-09-30 | $18.09M | $609.84K | $17.98M | (m) | (m) | (m) | (m) | (m) | 29.66× |
| 2020-06-30 | $12.73M | $573.13K | $12.55M | (m) | (m) | (m) | (m) | (m) | 22.21× |
| 2020-03-31 | $12.72M | $443.52K | $12.59M | (m) | (m) | (m) | (m) | (m) | 28.67× |
| 2019-12-31 | $13.23M | $724.16K | $13.21M | (m) | (m) | (m) | (m) | (m) | 18.27× |
| 2019-09-30 | $5.11M | $483.67K | $4.49M | (m) | (m) | (m) | (m) | (m) | 10.56× |
| 2019-06-30 | $5.60M | $468.27K | $5.13M | (m) | (m) | (m) | (m) | (m) | 11.95× |
| 2019-03-31 | $6.35M | $579.99K | $5.88M | (m) | (m) | (m) | (m) | (m) | 10.96× |
| 2018-12-31 | $7.25M | $399.55K | $6.89M | (m) | (m) | (m) | (m) | (m) | 18.15× |
| 2018-09-30 | $7.89M | $311.89K | $7.62M | (m) | (m) | (m) | (m) | (m) | 25.29× |
| 2018-06-30 | $7.65M | $323.06K | $7.42M | (m) | (m) | (m) | (m) | (m) | 23.67× |
| 2018-03-31 | $8.35M | $290.60K | $8.17M | (m) | (m) | (m) | (m) | (m) | 28.73× |
| 2017-12-31 | $9.13M | $311.87K | $8.98M | (m) | (m) | (m) | (m) | (m) | 29.28× |
| 2016-12-31 | $2.10M | $64.51K | $2.07M | (m) | (m) | (m) | (m) | (m) | 32.48× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |